Cargando…

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Ryu, Nagata, Kazuyoshi, Fukushima, Masanori, Haraguchi, Masafumi, Miuma, Satoshi, Miyaaki, Hisamitsu, Soyama, Akihiko, Hidaka, Masaaki, Eguchi, Susumu, Shigeno, Masaya, Yamashima, Mio, Yamamichi, Shinobu, Ichikawa, Tatsuki, Kugiyama, Yuki, Yatsuhashi, Hiroshi, Nakao, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834002/ https://www.ncbi.nlm.nih.gov/pubmed/35159095 http://dx.doi.org/10.3390/cancers14030827

Ejemplares similares

Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
por: Sasaki, Ryu, et al.
Publicado: (2019)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease
por: Yamashima, Mio, et al.
Publicado: (2019)

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
por: Kuwahara, Ai, et al.
Publicado: (2020)

Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study
por: Fukushima, Masanori, et al.
Publicado: (2022)

Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus
por: Ichikawa, Tatsuki, et al.
Publicado: (2020)

Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease
por: Ichikawa, Tatsuki, et al.
Publicado: (2021)

Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide
por: Okamura, Takuma, et al.
Publicado: (2022)

The Kupffer Cell Number Affects the Outcome of Living Donor Liver Transplantation from Elderly Donors
por: Hidaka, Masaaki, et al.
Publicado: (2016)

Elevated Fasting Plasma Glucose before Liver Transplantation is Associated with Lower Post-Transplant Survival
por: Katsura, Emi, et al.
Publicado: (2016)

Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial
por: Haraguchi, Masafumi, et al.
Publicado: (2021)

Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report
por: Hidaka, Masaaki, et al.
Publicado: (2011)

Two difficulty diagnosis cases of severe veno-occlusive disease
por: Miyaaki, Hisamitsu, et al.
Publicado: (2013)

Fully covered metallic stents for anastomotic biliary strictures after living donor liver transplantation
por: Komatsu, Naohiro, et al.
Publicado: (2023)

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
por: Tamura, Yosuke, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Association Between Trough Level of Tacrolimus and Change in Estimated Glomerular Filtration Rate 1 Year After Living Donor Liver Transplantation
por: Muta, Kumiko, et al.
Publicado: (2021)

Intrahepatic MicroRNA Profile of Liver Transplant Recipients with Hepatitis C Virus Co-Infected with Human Immunodeficiency Virus
por: Miyaaki, Hisamitsu, et al.
Publicado: (2017)

Evolution of Liver Transplantation Over the Last 2 Decades Based on a Single-Center Experience of 300 Cases
por: Soyama, Akihiko, et al.
Publicado: (2023)

Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
por: Ricke, Jens, et al.
Publicado: (2020)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

Inferior Vena Cava Anomalies with Portal Vein System Continuation Presenting as Portal Hypertension with a Long-term Follow-up
por: Fukushima, Masanori, et al.
Publicado: (2020)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
por: Kubo, Akinori, et al.
Publicado: (2021)

Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients
por: Miyaaki, Hisamitsu, et al.
Publicado: (2020)

The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection
por: Matsumoto, Kosuke, et al.
Publicado: (2022)

Prediction of Liver Prognosis from Pre-Transplant Renal Function Adjusted by Diuretics and Urinary Abnormalities in Adult-to-Adult Living Donor Liver Transplantation
por: Kitamura, Mineaki, et al.
Publicado: (2020)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition
por: Ulloa, Jose L, et al.
Publicado: (2013)

Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?
por: Plaikner, M., et al.
Publicado: (2018)

Long‐term outcomes of living‐donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three <3‐cm nodules in a single institute
por: Hidaka, Masaaki, et al.
Publicado: (2022)

Geranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in cultured human hepatic stellate cells and reduces liver fibrosis in carbon tetrachloride-treated mice
por: Senoo, Takemasa, et al.
Publicado: (2018)

Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients
por: Sasaki, Ryu, et al.
Publicado: (2023)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level
por: Hino, Naoyuki, et al.
Publicado: (2021)

The MR imaging diagnosis of liver diseases using gadoxetic acid: Emphasis on hepatobiliary phase
por: Jeong, Woo Kyoung, et al.
Publicado: (2013)

Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI
por: van Kessel, C. S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_an40id325qhm84dssfd8c87557